(NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B) (NN subunit) (NN p65) (NN mRNA) (NN accumulation)) (PP (IN in) (NP (NP (JJ lipopolysaccharide-stimulated) (JJ human) (JJ monocytic) (NNS cells)) (VP (VBN treated) (NP (-NONE- *)) (PP (IN with) (NP (NN sodium) (NN salicylate)))))))) (. .))
(S (NP-SBJ (NN Lipopolysaccharide)) (VP (VBZ is) (NP-PRD (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN trigger) (NNS substances)) (PP (IN for) (NP-COOD (NP (NNS monocytes)) (CC and) (NP (NNS macrophages)))) (VP (VBG causing) (NP (NP (NN secretion)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS mediators)) (PP (JJ such) (IN as) (NP-COOD (NP (NN tumor) (NN necrosis) (NN factor)) (CC and) (NP (NN interleukin-1)))))))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN nature)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NNS factors)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (NP (NN regulation)) (PP (IN of) (NP (DT these) (NN cytokine) (NNS genes))))))))) (VP (VBZ is) (ADVP-TMP (RB still)) (ADJP-PRD (JJ unknown))) (. .))
(S (NP-SBJ-38 (NP (NP (JJ Nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NP (NN NF-kappa) (NN B)) (: ;) (NP (NP (NN heterodimer)) (PP (IN of) (NP-COOD (NP (NN p50)) (CC and) (NP (NN p65)))))) (-RRB- -RRB-))) (NNS proteins)) (VP (VBP have) (VP (VBN been) (VP (VBN suggested) (S (NP-SBJ (-NONE- *-38)) (VP (TO to) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NN gene) (NN transcription)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators))))) (SBAR-TMP (WHADVP-39 (WRB when)) (S (NP-SBJ-40 (NNS monocytes)) (VP (VBP are) (VP (VBN stimulated) (NP (-NONE- *-40)) (PP (IN with) (NP (NN lipopolysaccharide))) (ADVP (-NONE- *T*-39)))))))))))) (. .))
(S-COOD (S (NP-SBJ-41 (NP (JJ Nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PP (JJ such) (IN as) (NP (NNS salicylates)))) (VP (VBP have) (VP (VBN been) (VP (VBN used) (NP-42 (-NONE- *-41)) (S (NP-SBJ (-NONE- *-42)) (VP (TO to) (VP (VB treat) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN inflammation))))))))))) (, ,) (CC and) (S (NP-SBJ-43 (NP (DT a) (JJ new) (NN mechanism)) (PP (IN of) (NP (NN drug) (NN action)))) (VP (VBD was) (VP (VBN suggested) (NP (-NONE- *-43)) (ADVP-TMP (RB recently))))) (. .))
(S (NP-SBJ-44 (NNS Salicylates)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (NP-SBJ-45 (-NONE- *-44)) (VP (TO to) (VP (VB inhibit) (NP (JJ lipopolysaccharide-induced) (NN gene) (NN transcription)) (PP (IN via) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN activation))))) (PP (IN by) (S (NP-SBJ (-NONE- *-45)) (VP-COOD (VP (VBG preventing) (NP (NP (DT the) (NN degradation)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN inhibitor) (`` ") (NN I) (NN kappa) (NN B) ('' "))))) (, ,) (VP (VBG blocking) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN into) (NP (DT the) (JJ nuclear) (NN compartment)))))))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ-46 (NP (DT the) (NN nature)) (PP (IN of) (NP (NP (DT the) (NN subunit)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (DT this) (NN mechanism))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN defined) (NP (-NONE- *-46))))) (. .))
(S (S (NP-SBJ (-NONE- *)) (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP-47 (IN by) (WHNP (WDT which))) (S (NP-SBJ (NNS salicylates)) (VP (VBP affect) (NP (NN cytokine) (NN gene) (NN transcription)) (PP (-NONE- *T*-47))))))))) (, ,) (NP-SBJ-48 (NP (DT the) (NN amount)) (PP (IN of) (NP-COOD (NP (ADJP-COOD (ADJP (JJ active)) (CC and) (ADJP (JJ inactive))) (NN NF-kappa) (NN B)) (CC and) (NP (NN NF-kappa) (NN B) (NN mRNA)))) (, ,) (PP (IN in) (NP (NN Porphyromonas) (NN gingivalis) (JJ lipopolysaccharide-stimulated) (JJ human) (JJ monocytic) (NNS cells)))) (VP (VBD was) (VP (VBN assessed) (NP (-NONE- *-48)))) (. .))
(S-COOD (S (NP-SBJ (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NN sodium) (NN salicylate)))) (VP (VBD suppressed) (NP (NN NF-kappa) (NN B) (NN p65) (NN mRNA) (NN accumulation)) (, ,) (S (NP-SBJ (-NONE- *)) (VP (VBG resulting) (PP (IN in) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ total) (NN NF-kappa) (NN B))))))))) (, ,) (S (NP-SBJ (NP (NN p50)) (PP (IN on) (NP (NN tissue) (NN oligonucleotide)))) (VP (VBD had) (NP (DT no) (NNS effects)) (PP (IN on) (NP (JJ lipopolysaccharide-induced) (NN NF-kappa) (NN B) (NN activation))))) (. .))
(S (NP-SBJ (DT The) (NNS data)) (VP-COOD (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-50 (NP (DT the) (NN p65) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBZ is) (VP (VBN inhibited) (NP (-NONE- *-50)) (PP (IN by) (NP-LGS (NN salicylate) (NN treatment)))))))) (CC and) (VP (VBP highlight) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN salicylate))) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (NN gene) (NN expression)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators)))))))))) (. .))
